Pathogenesis-Based Therapy With Repurposed Biologics for Monogenic Inflammatory Skin Disorders
- PMID: 32459286
- DOI: 10.1001/jamadermatol.2020.1018
Pathogenesis-Based Therapy With Repurposed Biologics for Monogenic Inflammatory Skin Disorders
Comment on
-
Secukinumab Therapy for Netherton Syndrome.JAMA Dermatol. 2020 Aug 1;156(8):907-911. doi: 10.1001/jamadermatol.2020.1019. JAMA Dermatol. 2020. PMID: 32459284 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical